Neoadjuvant systemic treatment of breast cancer

Journal of Surgical Oncology

Volumn 103, Issue 4, 2011, Pages 348-357

  Makhoul, Issam ^a   Kiwan, Elias ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Breast cancer; Chemotherapy; Endocrine therapy; Pathologic complete response; Primary systemic treatment

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; PACLITAXEL; PREDNISONE; TAXANE DERIVATIVE; TRASTUZUMAB; VINCRISTINE;

ADJUVANT THERAPY; BREAST CANCER; BREAST SURGERY; CANCER STAGING; CANCER SURVIVAL; CHEMOSENSITIVITY; HUMAN; MYOCARDIAL DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SENTINEL LYMPH NODE; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; MASTECTOMY; NEOADJUVANT THERAPY; PATIENT SELECTION;

EID: 79952019426     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21696     Document Type: Review

References (103)

1. Bonadonna G, Veronesi U, Brambilla C, et al.: Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst 1990;82:1539-1545. (Pubitemid 20296503)
2. Sachelarie I, Grossbard ML, Chadha M, et al.: Primary systemic therapy of breast cancer. Oncologist 2006;11:574-589. (Pubitemid 43967613)
3. Fisher B, Brown A, Mamounas E, et al.: Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997;15:2483-2493. (Pubitemid 27289876)
4. Mauri D, Pavlidis N, Ioannidis JP: Neoadjuvant versus adjuvant systemic treatment in breast cancer: A meta-analysis. J Natl Cancer Inst 2005;97:188-194. (Pubitemid 40277368)
5. Fisher B, Bryant J, Wolmark N, et al.: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998;16:2672-2685. (Pubitemid 28363030)
6. van der Hage JA, van de Velde CJ, Julien JP, et al.: Preoperative chemotherapy in primary operable breast cancer: Results from the European Organization for Research and Treatment of Cancer Trial 10902. J Clin Oncol 2001;19:4224-4237.
7. Jakesz R: Preliminary results of adjuvant CMF. 1st Joint Meeting of the German, Austrian, and Swiss Societies of Senology, 2000.
8. Scholl SM, Fourquet A, Asselain B, et al.: Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: Preliminary results of a randomised trial: S6. Eur J Cancer 1994;30A:645-652. (Pubitemid 24164252)
9. Schrag D, Garewal HS, Burstein HJ, et al.: American Society of Clinical Oncology Technology Assessment: Chemotherapy sensitivity and resistance assays. J Clin Oncol 2004;22:3631-3638. (Pubitemid 41103670)
10. Hwu P, Bedikian AY, Grimm EA: Challenges of chemosensitivity testing. Clin Cancer Res 2006;12:5258-5259. (Pubitemid 44497234)
11. Rastogi P, Anderson SJ, Bear HD, et al.: Preoperative chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 2008; 26:778-785. (Pubitemid 351264391)
12. Berruti A, Brizzi MP, Generali D, et al.: Presurgical systemic treatment of nonmetastatic breast cancer: Facts and open questions. Oncologist 2008;13:1137-1148.
13. Anderson WF, Schairer C, Chen BE, et al.: Epidemiology of inflammatory breast cancer (IBC). Breast Dis 2005;22:9-23. (Pubitemid 44308938)
14. Overmoyer BA: Inflammatory breast cancer: Novel preoperative therapies. Clin Breast Cancer 2010;10:27-32.
15. Gunduz N, Fisher B, Saffer EA: Effect of surgical removal on the growth and kinetics of residual tumor. Cancer Res 1979;39: 3861-3865. (Pubitemid 10242198)
16. Fisher B, Gunduz N, Saffer EA: Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases. Cancer Res 1983;43:1488-1492. (Pubitemid 13122535)
17. Fisher B, Gunduz N, Coyle J, et al.: Presence of a growth-stimulating factor in serum following primary tumor removal in mice. Cancer Res 1989;49:1996-2001. (Pubitemid 19106503)
18. Fisher B, Saffer E, Rudock C, et al.: Effect of local or systemic treatment prior to primary tumor removal on the production and response to a serum growth-stimulating factor in mice. Cancer Res 1989;49:2002-2004. (Pubitemid 19106504)
19. Liu SV, Melstrom L, Yao K, et al.: Neoadjuvant therapy for breast cancer. J Surg Oncol 2010;101:283-291.
20. Jeruss JS, Mittendorf EA, Tucker SL, et al.: Staging of breast cancer in the neoadjuvant setting. Cancer Res 2008;68:6477-6481.
21. Buchholz TA, Lehman CD, Harris JR, et al.: Statement of the science concerning locoregional treatments after preoperative chemotherapy for breast cancer: A National Cancer Institute Conference. J Clin Oncol 2008;26:791-797. (Pubitemid 351265334)
22. Lehman CD, Gatsonis C, Kuhl CK, et al.: MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer. N Engl J Med 2007;356:1295-1303. (Pubitemid 46513295)
23. Partridge SC, Mullins CD, Kurland BF, et al.: Apparent diffusion coefficient values for discriminating benign and malignant breast MRI lesions: Effects of lesion type and size. AJR Am J Roentgenol 2010;194:1664-1673.
24. Orel SG, Schnall MD: MR imaging of the breast for the detection, diagnosis, and staging of breast cancer. Radiology 2001;220:13-30. (Pubitemid 32577955)
25. Elsamaloty H, Elzawawi MS, Mohammad S, et al.: Increasing accuracy of detection of breast cancer with 3-T MRI. AJR Am J Roentgenol 2009;192:1142-1148.
26. Buzdar AU, Singletary SE, Theriault RL, et al.: Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol 1999;17:3412-3417. (Pubitemid 29517908)
27. Smith IC, Heys SD, Hutcheon AW, et al.: Neoadjuvant chemotherapy in breast cancer: Significantly enhanced response with docetaxel. J Clin Oncol 2002;20:1456-1466. (Pubitemid 34260523)
28. Dieras V, Fumoleau P, Romieu G, et al.: Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer. J Clin Oncol 2004;22:4958-4965. (Pubitemid 46638621)
29. Evans TR, Yellowlees A, Foster E, et al.: Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: An Anglo-Celtic Cooperative Oncology Group Study. J Clin Oncol 2005;23:2988-2995. (Pubitemid 46224118)
30. Gianni L, Baselga J, Eiermann W, et al.: Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clin Cancer Res 2005;11:8715-8721. (Pubitemid 43005921)
31. Green MC, Buzdar AU, Smith T, et al.: Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol 2005;23:5983-5992.
32. von Minckwitz G, Raab G, Caputo A, et al.: Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: The GEPAR-DUO Study of the German Breast Group. J Clin Oncol 2005;23:2676-2685. (Pubitemid 46179457)
33. Steger GG, Galid A, Gnant M, et al.: Pathologic complete response with six compared with three cycles of neoadjuvant epirubicin plus docetaxel and granulocyte colony-stimulating factor in operable breast cancer: Results of ABCSG-14. J Clin Oncol 2007;25:2012-2018. (Pubitemid 46972785)
34. von Minckwitz G, Kummel S, Vogel P, et al.: Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: Phase III randomized GeparTrio trial. J Natl Cancer Inst 2008;100:542-551.
35. von Minckwitz G, Kummel S, Vogel P, et al.: Intensified neoadjuvant chemotherapy in early-responding breast cancer: Phase III randomized GeparTrio study. J Natl Cancer Inst 2008;100:552-562.
36. von Minckwitz G, Rezai M, Loibl S, et al.: Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: Phase III GeparQuattro study. J Clin Oncol 2010;28:2015-2023.
37. Therasse P, Mauriac L, Welnicka-Jaskiewicz M, et al.: Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: An EORTC-NCIC-SAKK multicenter study. J Clin Oncol 2003; 21:843-850. (Pubitemid 46606444)
38. Eiermann W, Paepke S, Appfelstaedt J, et al.: Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study. Ann Oncol 2001;12:1527-1532. (Pubitemid 34065880)
39. Smith IE, Dowsett M, Ebbs SR, et al.: Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: The Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 2005;23:5108-5116. (Pubitemid 46224019)
40. Dowsett M, Ebbs SR, Dixon JM, et al.: Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer - A study from the IMPACT trialists. J Clin Oncol 2005;23:2477-2492. (Pubitemid 47050838)
41. Cataliotti L, Buzdar AU, Noguchi S, et al.: Comparison of anastrozole versus tamoxifen as preoperative therapy in post-menopausal women with hormone receptor-positive breast cancer: The Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial. Cancer 2006;106:2095-2103.
42. Hurley J, Doliny P, Silva O, et al.: Neoadjuvant herceptin/ taxotere/cisplatin in the treatment of locally advanced and inflammatory breast cancer. Proc Am Soc Clin Oncol 2002;20: 50a.
43. Burstein HJ, Harris LN, Gelman R, et al.: Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/ cyclophosphamide for HER2 overexpressing stage II or III breast cancer: A pilot study. J Clin Oncol 2003;21:46-53.
44. Bines J, Murad A, Lago S: Weekly docetaxel (taxotere) and trastuzumab (herceptin) as primary therapy in stage III, HER-2 overexpressing breast cancer - A Brazilian multicenter study. Breast Cancer Res Treat 2003;82:S56.
45. Buzdar AU, Ibrahim NK, Francis D, et al.: Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005;23:3676-3685.
46. Coudert BP, Largillier R, Arnould L, et al.: Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: Results of the GETN(A)-1 trial. J Clin Oncol 2007;25:2678-2684. (Pubitemid 47123173)
47. Sikov WM, Dizon DS, Strenger R, et al.: Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: A Brown University Oncology Group Study. J Clin Oncol 2009;27:4693-4700.
48. Untch M, Rezai M, Loibl S, et al.: Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: Results from the GeparQuattro study. J Clin Oncol 2010;28:2024-2031.
49. Hyams DM, Leichman GC, Klein P, et al.: Phase II trial of neoadjuvant pegylated liposomal doxorubicin with paclitaxel and trastuzumab in patients with operable Her2-positive breast cancer, SABCS, 2009.
50. Chollet P, Amat S, Cure H, et al.: Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer. Br J Cancer 2002;86:1041-1046. (Pubitemid 34441058)
51. Guarneri V, Broglio K, Kau SW, et al.: Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 2006;24:1037-1044. (Pubitemid 46638799)
52. Dawood S, Broglio K, Kau SW, et al.: Prognostic value of initial clinical disease stage after achieving pathological complete response. Oncologist 2008;13:6-15. (Pubitemid 351206692)
53. Bear HD, Anderson S, Brown A, et al.: The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2003;21:4165-4174. (Pubitemid 46606185)
54. Kaufmann M, Hortobagyi GN, Goldhirsch A, et al.: Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: An update. J Clin Oncol 2006;24:1940-1949. (Pubitemid 46638994)
55. Thomas E, Holmes FA, Smith TL, et al.: The use of alternate, non-cross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: Long-term results from a prospective randomized trial. J Clin Oncol 2004; 22:2294-2302. (Pubitemid 41115385)
56. Ogston KN, Miller ID, Payne S, et al.: A new histological grading system to assess response of breast cancers to primary chemotherapy: Prognostic significance and survival. Breast 2003;12:320-327. (Pubitemid 37322062)
57. Honkoop AH, van Diest PJ, de Jong JS, et al.: Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer. Br J Cancer 1998;77:621-626. (Pubitemid 28059470)
58. Kurosumi M: Significance and problems in evaluations of pathological responses to neoadjuvant therapy for breast cancer. Breast Cancer 2006;13:254-259.
59. Chevallier B, Roche H, Olivier JP, et al.: Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FECHD) results in a high histologic response rate. Am J Clin Oncol 1993;16:223-228. (Pubitemid 23184384)
60. Kuerer HM, Newman LA, Smith TL, et al.: Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999;17:460-469. (Pubitemid 29075229)
61. Hennessy BT, Hortobagyi GN, Rouzier R, et al.: Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. J Clin Oncol 2005;23:9304-9311.
62. Mazouni C, Peintinger F, Wan-Kau S, et al.: Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome. J Clin Oncol 2007;25:2650-2655. (Pubitemid 47123169)
63. Bottini A, Berruti A, Brizzi MP, et al.: Cytotoxic and antiproliferative activity of the single agent epirubicin versus epirubicin plus tamoxifen as primary chemotherapy in human breast cancer: A single-Institution Phase III Trial. Endocr Relat Cancer 2005;12:383-392. (Pubitemid 40896453)
64. Jones RL, Lakhani SR, Ring AE, et al.: Pathological complete response and residual DCIS following neoadjuvant chemotherapy for breast carcinoma. Br J Cancer 2006;94:358-362. (Pubitemid 43237560)
65. Colleoni M, Viale G, Zahrieh D, et al.: Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: A study of preoperative treatment. Clin Cancer Res 2004;10:6622-6628. (Pubitemid 39346559)
66. Jones RL, Salter J, A'Hern R, et al.: Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer. Breast Cancer Res Treat 2010;119:315-323.
67. Caudle AS, Gonzalez-Angulo AM, Hunt KK, et al.: Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2010;28:1821-1828.
68. Hannemann J, Oosterkamp HM, Bosch CA, et al.: Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2005;23:3331-3342.
69. Peintinger F, Anderson K, Mazouni C, et al.: Thirty-gene pharmacogenomic test correlates with residual cancer burden after preoperative chemotherapy for breast cancer. Clin Cancer Res 2007;13:4078-4082. (Pubitemid 47105968)
70. Wright FC, Zubovits J, Gardner S, et al.: Optimal assessment of residual disease after neo-adjuvant therapy for locally advanced and inflammatory breast cancer-Clinical examination, mammography, or magnetic resonance imaging? J Surg Oncol 2010; 101:604-610.
71. Chagpar AB, Middleton LP, Sahin AA, et al.: Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy. Ann Surg 2006;243:257-264. (Pubitemid 43185446)
72. Akazawa K, Tamaki Y, Taguchi T, et al.: Preoperative evaluation of residual tumor extent by three-dimensional magnetic resonance imaging in breast cancer patients treated with neoadjuvant chemotherapy. Breast J 2006;12:130-137.
73. Segara D, Krop IE, Garber JE, et al.: Does MRI predict pathologic tumor response in women with breast cancer undergoing preoperative chemotherapy? J Surg Oncol 2007;96:474-480.
74. Chen JH, Feig B, Agrawal G, et al.: MRI evaluation of pathologically complete response and residual tumors in breast cancer after neoadjuvant chemotherapy. Cancer 2008;112:17-26.
75. Denis F, Desbiez-Bourcier AV, Chapiron C, et al.: Contrast enhanced magnetic resonance imaging underestimates residual disease following neoadjuvant docetaxel based chemotherapy for breast cancer. Eur J Surg Oncol 2004;30:1069-1076. (Pubitemid 40267811)
76. Straver ME, Loo CE, Rutgers EJ, et al.: MRI-model to guide the surgical treatment in breast cancer patients after neoadjuvant chemotherapy. Ann Surg 2010;251:701-707.
77. Hodgson NC, Gulenchyn KY: Is there a role for positron emission tomography in breast cancer staging? J Clin Oncol 2008;26:712-720.
78. Mukherjee SD, Dhamanaskar K, Tozer R, et al.: A prospective study to evaluate the role of 2-[18f] fluoro-2-deoxy-D-glucose (FDG)-positron emission tomography (PET), breast magnetic resonance imaging (MRI), and breast ultrasonography in monitoring tumor responses in patients with locally advanced breast cancer (LABC) undergoing neoadjuvant chemotherapy. J Clin Oncol 2010;28:15s (suppl; abstr 595).
79. Martoni A, Zamagni C, Quercia S, et al.: Predictive role of [18F]FDG-PET early evaluation in patients (pts) undergoing preoperative chemotherapy (PCT) for breast cancer (BC). J Clin Oncol 2010;28:15s (suppl; abstr 635).
80. Jung SY, Kim SK, Nam BH, et al.: Prognostic impact of [18F] FDG-PET in operable breast cancer treated with neoadjuvant chemotherapy. Ann Surg Oncol 2010;17:247-253.
81. Davidson NE, Morrow M: Sometimes a great notion - An assessment of neoadjuvant systemic therapy for breast cancer. J Natl Cancer Inst 2005;97:159-161. (Pubitemid 40277358)
82. Peintinger F, Kuerer HM, McGuire SE, et al.: Residual specimen cellularity after neoadjuvant chemotherapy for breast cancer. Br J Surg 2008;95:433-437.
83. Chen AM, Meric-Bernstam F, Hunt KK, et al.: Breast conservation after neoadjuvant chemotherapy: The MD Anderson Cancer Center experience. J Clin Oncol 2004;22:2303-2312. (Pubitemid 41115386)
84. Beriwal S, Schwartz GF, Komarnicky L, et al.: Breast-conserving therapy after neoadjuvant chemotherapy: Long-term results. Breast J 2006;12:159-164.
85. Garimella V, Qutob O, Fox JN, et al.: Recurrence rates after DCE-MRI image guided planning for breast-conserving surgery following neoadjuvant chemotherapy for locally advanced breast cancer patients. Eur J Surg Oncol 2007;33:157-161. (Pubitemid 46336549)
86. Huang EH, Tucker SL, Strom EA, et al.: Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy. J Clin Oncol 2004;22:4691-4699.
87. Partridge SC, Gibbs JE, Lu Y, et al.: MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival. AJR Am J Roentgenol 2005;184: 1774-1781. (Pubitemid 40770147)
88. Weatherall PT, Evans GF, Metzger GJ, et al.: MRI vs. histologic measurement of breast cancer following chemotherapy: Comparison with X-ray mammography and palpation. J Magn Reson Imaging 2001;13:868-875. (Pubitemid 32479944)
89. Mamounas EP, Brown A, Anderson S, et al.: Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: Results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2005;23:2694-2702. (Pubitemid 46179459)
90. Xing Y, Foy M, Cox DD, et al.: Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer. Br J Surg 2006;93:539-546.
91. Classe JM, Bordes V, Campion L, et al.: Sentinel lymph node biopsy after neoadjuvant chemotherapy for advanced breast cancer: Results of Ganglion Sentinelle et Chimiotherapie Neoadjuvante, a French prospective multicentric study. J Clin Oncol 2009;27:726-732.
92. Kaufmann M, Morrow M, von Minckwitz G, et al.: Locoregional treatment of primary breast cancer: Consensus recommendations from an International Expert Panel. Cancer 2010;116:1184-1191.
93. Krag DN, Anderson SJ, Julian TB, et al.: Primary outcome results of NSABP B-32, a randomized phase III clinical trial to compare sentinel node resection (SNR) to conventional axillary dissection (AD) in clinically node-negative breast cancer patients. J Clin Oncol 2010;28:18s (suppl; abstr LBA505).
94. Giuliano AE, McCall LM, Beitsch PD, et al.: ACOSOG Z0011: A randomized trial of axillary node dissection in women with clinical T 1-2 N0 M0 breast cancer who have a positive sentinel node. J Clin Oncol 2010;28:18s (suppl; abstr CRA506).
95. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomised trials. Lancet 366: 2087-2106.
96. Schnaper LA, Hughes KS: The use of radiation in the elderly. Breast Cancer Online 2007;10:1-3.
97. Hughes KS, Schnaper LA, Berry D, et al.: Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med 2004;351:971-977. (Pubitemid 39166260)
98. Schonberg MA, Marcantonio ER, Li D, et al.: Breast cancer among the oldest old: Tumor characteristics, treatment choices, and survival. J Clin Oncol 2010;28:2038-2045.
99. Caudle AS, Gonzalez-Angulo AM, Hunt KK, et al.: Impact of progression during neoadjuvant chemotherapy on operative management of breast cancer, SABCS, 2009.
100. Normanno N, Morabito A, De Luca A, et al.: Target-based therapies in breast cancer: Current status and future perspectives. Endocr Relat Cancer 2009;16:675-702.
101. Landis MD, Pavlick A, Dobrolecki L, et al.: Targeting intrinsically-resistant breast cancer stem cells with gamma-secretase inhibitors, SABCS, 2009.
102. Li X, Lewis MT, Huang J, et al.: Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 2008;100:672-679.
103. Creighton CJ, Li X, Landis M, et al.: Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci USA 2009;106: 13820-13825.